Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kudingxiang Tong Qi is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Renmin Hospital of Peking University (also known as Renmin Hospital of Beijing University) for the management of postoperative ileus (POI). The preparation is primarily derived from the pedicel of *Cucumis melo* L., known as Kudingxiang or Melo Pedicellus in TCM. It contains bioactive cucurbitacins that are thought to stimulate gastrointestinal motility. Administered rectally via enema or drip, Kudingxiang Tong Qi is used to accelerate the recovery of bowel function following abdominal surgery, specifically by promoting the early passage of flatus and defecation. It is a recognized hospital-made pharmaceutical within the Chinese regulatory framework for TCM and is distinct from Kuding tea (*Ilex kudingcha*).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kudingxiang Tong Qi.